(MedPage Today) — Despite substantial health benefits, two GLP-1 receptor agonists weren’t cost-effective at their current prices, according to an economic evaluation that compared four anti-obesity medications.
Net prices of tirzepatide (Mounjaro…
Source link : https://www.medpagetoday.com/primarycare/obesity/114656
Author :
Publish date : 2025-03-14 15:50:00
Copyright for syndicated content belongs to the linked Source.
